FOR IN VITRO AND PRE-CLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE
Metabolic

SLU-PP-332 5mg

5mg ERR agonist research compound

From€49.00
In Stock · Ships within 48h
Reviews coming soonBe among the first to share your research experience.
Download Certificate of Analysis
  • EU Dispatch
  • CoA Included — Every Batch
  • Discreet Packaging
Purity≥98% HPLC
FormLyophilised Powder
Storage2–8°C
OriginEuropean Stock
DispatchWithin 48h
SKUUL-SLU-5MG
≥98% PureHPLC verified
HPLC TestedDual identity check
EU DispatchShips within 48h
CoA Incl.Every batch
Research Profile

Why SLU-PP-332 Fascinates Researchers

SLU-PP-332 is a potent synthetic agonist of estrogen-related receptor alpha (ERRα), a nuclear transcription factor that functions as a master regulator of mitochondrial biogenesis, oxidative metabolism, and exercise-adaptive gene expression. Its designation as an "exercise mimetic" reflects preclinical data demonstrating that its pharmacological activation of ERRα recapitulates elements of the transcriptional and physiological response to endurance exercise — without the contractile activity itself.

ERRα: The Orphan Receptor at the Centre of Exercise Biology

ERRα (estrogen-related receptor alpha, gene name ESRRA) is a member of the nuclear receptor superfamily that was classified as an orphan receptor due to the absence of an identified endogenous ligand. Despite lacking a classical hormone ligand, ERRα is constitutively active and controls the expression of hundreds of genes in oxidative metabolism pathways — particularly in tissues with high energy demand such as skeletal muscle, heart, and brown adipose tissue. Its transcriptional targets include PGC-1α, cytochrome c oxidase subunits, fatty acid oxidation enzymes, and genes governing mitochondrial biogenesis. Exercise-induced PGC-1α expression potently coactivates ERRα, establishing this nuclear receptor as a critical node in the exercise-response transcriptional network.

Pharmacological Profile & Preclinical Evidence

SLU-PP-332 was developed by Thomas Burris's group at Washington University as a highly selective, cell-permeable ERRα agonist. It binds to the ligand-binding domain of ERRα and stabilises the receptor in an active conformation that recruits transcriptional coactivators, reproducing many of the genomic responses normally triggered by exercise-induced PGC-1α coactivation. ERRβ and ERRγ selectivity profiling confirms that SLU-PP-332 has substantially greater activity at ERRα than at the related receptor subtypes, making it a useful tool for dissecting ERRα-specific biology.

Preclinical studies have reported that SLU-PP-332 administration in sedentary mice upregulates oxidative phosphorylation gene sets, increases mitochondrial content in skeletal muscle, and improves exercise capacity (assessed by treadmill running distance) beyond that achievable by the vehicle-treated sedentary controls. These findings have generated significant interest in SLU-PP-332 as a pharmacological tool for studying the molecular basis of exercise adaptation, particularly in contexts where physical exercise is not feasible.

Research Applications

Beyond exercise biology, SLU-PP-332 has potential applications as a research tool in cardiac metabolism (ERRα is highly expressed in cardiomyocytes), brown adipose thermogenesis research, and studies of mitochondrial biogenesis in ageing models. Its well-characterised selectivity profile and cell permeability make it a practical in vitro and in vivo tool for nuclear receptor biology investigations.

This content is for informational purposes only and reflects the state of preclinical research. It does not constitute medical advice, endorsement of human use, or therapeutic claims of any kind.

Manufacturing Standards

Our Quality Commitment

HPLC Verified

Purity confirmed by High-Performance Liquid Chromatography at an accredited EU laboratory.

≥98% Purity

Every batch meets or exceeds 98% purity. CoA available for verification before dispatch.

Batch Traceability

Each vial is traceable to its synthesis batch, testing date, and analytical records.

Cold Chain Storage

European stock stored at optimal temperature from synthesis to dispatch.

48h EU Dispatch

Orders ship from EU stock within 48 hours with discrete, temperature-appropriate packaging.

CoA Included

Certificate of Analysis issued for every batch, available for download on request.

Download CoA for SLU-PP-332 5mg
Peer-Reviewed Literature

Key Scientific Studies

Peer-reviewed research supporting SLU-PP-332 investigation.

[01]
Cvoro A, Tatomer D, Tee MK, et al. (2008) — Journal of Clinical Endocrinology & Metabolism

“Selective estrogen receptor-related receptor α modulation regulates metabolic gene expression”

Foundational characterisation of ERRα's role in metabolic gene regulation, establishing the receptor's broad transcriptional control over oxidative phosphorylation and fatty acid oxidation gene networks. Pharmacological modulation of ERRα activity is demonstrated to alter the expression of hundreds of metabolic genes in muscle and adipose tissue models.

View on PubMed
[02]
Dufour CR, Wilson BJ, Huss JM, et al. (2007) — Cell Metabolism

“Genome-Wide Orchestration of Cardiac Functions by the Orphan Nuclear Receptors ERRα and γ”

Genome-wide ChIP-chip analysis mapping ERRα binding sites across the cardiac genome. The study identifies ERRα as a master coordinator of cardiac metabolic gene expression, with binding enrichment at promoters of mitochondrial electron transport chain components, fatty acid oxidation enzymes, and TCA cycle genes — establishing the importance of ERRα biology for cardiac metabolism research.

View on PubMed
[03]
Murray J, Auwerx J, Huss JM. (2013) — Molecular and Cellular Biology

“Impaired myogenesis in estrogen-related receptor (ERR)α-deficient skeletal myocytes”

Investigation of ERRα's role in skeletal muscle development and function using ERRα knockout models. Loss of ERRα impairs myogenic differentiation, reduces mitochondrial content, and compromises oxidative metabolism — phenotypes that mirror elements of sarcopenic muscle in ageing, providing functional context for pharmacological ERRα activation as a potential tool in muscle biology research.

View on PubMed
[04]
Patch RJ, Searle LL, Kim AJ, et al. (2011) — Journal of Medicinal Chemistry

“Identification of diaryl ether-based ligands for estrogen-related receptor α as potential antidiabetic agents”

Medicinal chemistry study reporting the identification and characterisation of synthetic ERRα agonists including structural relatives of SLU-PP-332. SAR analysis defines key pharmacophore features for ERRα agonism and selectivity, and in vitro metabolic profiling confirms activation of oxidative phosphorylation gene programmes consistent with ERRα's transcriptional role.

View on PubMed

All studies referenced are independent third-party research. UNIK LAB makes no claims regarding the therapeutic efficacy of any compound and does not represent or endorse the conclusions of cited studies. All referenced research was conducted under controlled laboratory or clinical conditions; results may not be predictive of effects in other experimental contexts.

Common Questions

Research FAQ

Answers to the most frequently asked questions about SLU-PP-332.

Same Category

Similar Compounds

Other Metabolic research compounds from our catalogue.

Your Longevity Research Guide Awaits

Subscribe to receive new compound profiles, CoA updates, and curated research digests — delivered directly to your inbox.